论文部分内容阅读
冷吡啉相关周期性综合征(CAPS)是一种遗传性炎症型疾病,包括家族性寒冷型自身炎症性综合征(FCAS)和穆-韦二氏综合征(MWS)。该疾病的症状包括发热、寒战、皮疹、疲劳、关节痛和眼睛发红。促炎症反应细胞因子白介素-1(IL-1)为该病的致病因子,因此调节IL-1的活性成为缓解CAPS症状的重要治疗方法。利洛纳塞(IL-1受体阻滞剂)已通过美国FDA批准,用于治疗此罕见的炎症性疾病。利洛纳塞与IL-1b和IL-1a有高度的亲和性,与之结合并抑制IL-1的活性。文中对该药物作用机制、药动学、临床研究进展进行综述。
Cold-pyrexia-related periodic syndrome (CAPS) is a hereditary inflammatory disease that includes familial cold-type auto-inflammatory syndrome (FCAS) and Muhammad’s Disease (MWS). Symptoms of the disease include fever, chills, rash, fatigue, joint pain and redness of the eyes. The proinflammatory cytokine interleukin-1 (IL-1) is a causative agent of the disease and therefore regulating IL-1 activity is an important treatment for the relief of symptoms of CAPS. Rilonacese (IL-1 receptor blocker) has been approved by the U.S. FDA for the treatment of this rare inflammatory disease. Rilonsese has high affinity for IL-1b and IL-1a, binds to it and inhibits the activity of IL-1. In this paper, the mechanism of action of the drug, pharmacokinetics, clinical research progress are reviewed.